![Bernd O. Wetzel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bernd O. Wetzel
Corporate Officer/Principal en Atugen AG .
Cargos activos de Bernd O. Wetzel
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Atugen AG
![]() Atugen AG Pharmaceuticals: MajorHealth Technology Atugen AG is a biopharmaceutical company. It develops RNAi therapeutics which focus on vivo applications in oncology and liver diseases, exploiting its proprietary oligonucleotide delivery technologies and chemically stabilized siRNA structures. Founded in 1998, the company is headquartered in Berlin, Germany | Corporate Officer/Principal | - | - |
Historial de carrera de Bernd O. Wetzel
Antiguos cargos conocidos de Bernd O. Wetzel.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
DeveloGen AG
![]() DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Director/Miembro de la Junta | 05/11/2009 | 25/01/2012 |
SILENCE THERAPEUTICS PLC | Director/Miembro de la Junta | 05/10/2009 | 05/01/2010 |
DIREVO Biotech AG
![]() DIREVO Biotech AG Miscellaneous Commercial ServicesCommercial Services DIREVO Biotech AG researches on screening-based directed evolution of genes and proteins and applies its integrated proprietary technologies to the development of biopharmaceuticals, industrial enzymes, chemical biocatalysts and enzymes for food and feed. Its platform technologies combine efficient DNA variation methods for mutation and recombination of genes with ultra-high throughput screening technologies. The company was founded in 2000 and is headquartered in Cologne, Germany. | Director/Miembro de la Junta | - | 25/10/2007 |
BIOFRONTERA AG | Director/Miembro de la Junta | 01/05/2011 | - |
Ludwig-Maximilians-Universität München | Corporate Officer/Principal | - | - |
Gruner Böhringer AG
![]() Gruner Böhringer AG Engineering & ConstructionIndustrial Services Gruner Böhringer AG engages in the provision of engineering and planning services. It specializes in the areas of infrastructure construction, hydraulic and sanitary engineering, geomatics, geology, and geographic information systems. The company was founded in 1952 and is headquartered in Oberwil, Switzerland. | Director Técnico/Científico/I+D | - | - |
Biovertis AG
![]() Biovertis AG Pharmaceuticals: MajorHealth Technology Biovertis AG operates as a clinical stage pharmaceutical company. It develops small molecule drugs against proprietary microbial antigens. The firm discovers and develops antimicrobial drugs for infections caused by antibiotic-resistant bacterial pathogens. The company was founded by Erich Felber, Uwe von Ahsen, and Alexander Ullrich von Gabain in 2003 and is headquartered in Vienna, Austria. | Director/Miembro de la Junta | - | - |
Estadísticas
Internacional
Alemania | 6 |
Austria | 2 |
Suiza | 2 |
Operativa
Director/Board Member | 5 |
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Sectorial
Health Technology | 5 |
Commercial Services | 3 |
Industrial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
BIOFRONTERA AG | Health Technology |
SILENCE THERAPEUTICS PLC | Commercial Services |
Empresas privadas | 5 |
---|---|
DIREVO Biotech AG
![]() DIREVO Biotech AG Miscellaneous Commercial ServicesCommercial Services DIREVO Biotech AG researches on screening-based directed evolution of genes and proteins and applies its integrated proprietary technologies to the development of biopharmaceuticals, industrial enzymes, chemical biocatalysts and enzymes for food and feed. Its platform technologies combine efficient DNA variation methods for mutation and recombination of genes with ultra-high throughput screening technologies. The company was founded in 2000 and is headquartered in Cologne, Germany. | Commercial Services |
Biovertis AG
![]() Biovertis AG Pharmaceuticals: MajorHealth Technology Biovertis AG operates as a clinical stage pharmaceutical company. It develops small molecule drugs against proprietary microbial antigens. The firm discovers and develops antimicrobial drugs for infections caused by antibiotic-resistant bacterial pathogens. The company was founded by Erich Felber, Uwe von Ahsen, and Alexander Ullrich von Gabain in 2003 and is headquartered in Vienna, Austria. | Health Technology |
Gruner Böhringer AG
![]() Gruner Böhringer AG Engineering & ConstructionIndustrial Services Gruner Böhringer AG engages in the provision of engineering and planning services. It specializes in the areas of infrastructure construction, hydraulic and sanitary engineering, geomatics, geology, and geographic information systems. The company was founded in 1952 and is headquartered in Oberwil, Switzerland. | Industrial Services |
Atugen AG
![]() Atugen AG Pharmaceuticals: MajorHealth Technology Atugen AG is a biopharmaceutical company. It develops RNAi therapeutics which focus on vivo applications in oncology and liver diseases, exploiting its proprietary oligonucleotide delivery technologies and chemically stabilized siRNA structures. Founded in 1998, the company is headquartered in Berlin, Germany | Health Technology |
DeveloGen AG
![]() DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Health Technology |
- Bolsa de valores
- Insiders
- Bernd O. Wetzel
- Experiencia